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Cancer is initiated through both genetic and epigenetic alterations. The end-effect of such changes to the
DNA machinery is a set of uncontrolled mechanisms of cell division, invasion and, eventually, metastasis.
Epigenetic changes are now increasingly appreciated as an essential driver to the cancer phenotype. The
epigenetic regulation of cancer is complex and not yet fully understood, but application of epigenetics to
clinical practice and in cancer research has the potential to improve cancer care. Epigenetics changes do
not cause changes in the DNA base-pairs (and, hence, does not alter the genetic code per se) but rather
occur through methylation of DNA, by histone modifications, and, through changes to chromatin
structure to alter genetic expression. Epigenetic regulators are characterized as writers, readers or erasers
by their mechanisms of action. The human epigenome is influenced from cradle to grave, with internal
and external life-time exposure influencing the epigenetic marks that may act as modifiers or drivers of
carcinogenesis. Preventive and public health strategies may follow from better understanding of the life-
time influence of the epigenome. Epigenetics may be used to define risk, to investigate mechanisms of
carcinogenesis, to identify biomarkers, and to identify novel therapeutic options. Epigenetic alterations
are found across many solid cancers and are increasingly making clinical impact to cancer management.
Novel epigenetic drugs may be used for a more tailored and specific response to treatment of cancers. We
present a primer on epigenetics for surgical oncologists with examples from colorectal cancer, breast
cancer, pancreatic cancer and hepatocellular carcinoma.
© 2019 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Introduction
Understanding the processes driving the initiation, progression
and behaviour of solid tumours at the cellular level is a core part of
the curriculum for surgical oncologists [1]. As research and
knowledge surrounding cancer biology rapidly develops, previous
knowledge becomes outdated and requires updating. Thus, expe-
rienced and young surgeons alike require information to appreciate
the molecular biology of solid visceral tumours in order to under-
stand and deliver high quality cancer care.
Epigenetics - the study of molecular changes to the DNA that do
not arise from alterations in the DNA proper - is of utmost interesttinal Surgery, Stavanger Uni-
y.
r Ltd. This is an open access articleand importance for research into various diseases processes,
including cancer [2,3]. The epigenetic information in human cells is
influenced through various levels and continuously during a life-
time (Fig. 1) of exposures to both health promoting and potential
toxic factors [4]. Alterations may occur through genomic changes,
as an effect of internal or external exposures and through random
effects. Thus, epigenetics stands at the interface of the genome,
human development, and environmental exposure [5e7]. Conse-
quently, epigenetics may be influenced at several levels and at
various timepoints in humans to initiate or modify risk of disease
such as cancer. Indeed, cancer itself may alter the epigenetic code
through exposures and selection pressure during the various pha-
ses of malignant transformation.
Epigenetic alterations occur in concert with other genetic
changes (Fig. 2) to influence the genomics, transcriptomics and
proteomics that drive the cancer phenotype [3,5,8,9]. Epigeneticunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. Epigenetic influence through a lifetime of exposure, DNA interactions and cancer development.
Epigenetic alterations occur throughout a human life, from in utero exposure (left panel) until ageing processes start. The DNA interaction (middle panel) that occurs are mutually
interacting and influencing the cancer hallmarks for cancer risk and progression, for which current research seeks to explore the exact mechanisms a contribution throughout the
phases (right panel) of cancer development. The illustration is generic and unique patterns of exposure, risk and influence may occur to each specific cancer type.
Fig. 2. Overview of ‘omics’ in cancer regulation.
Epigenetics broadly occur as DNA methylation, histone modifications, and higher-order chromatin regulation. Epigenetics are influenced by the genome, transcriptome and pro-
teome and thus is an important part of the complexity of cancer development.
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chromatin remodellers, microRNAs, and other components of
chromatin [10]. Cancer genetics and epigenetics are linked in
generating the malignant phenotype; i.e. epigenetic changes can
cause mutations in genes (Fig. 1), and, conversely, mutations arefrequently observed in genes that modify the epigenome [9]. Epi-
genetics is increasingly becoming incorporated into routine clinical
practice, for example in glioblastoma multiforme, where O-6-
Methylguanine-DNA Methyltransferase (MGMT) methylation sta-
tus is used to guide Temozolomide therapy.
T.M. Drake, K. Søreide / European Journal of Surgical Oncology 45 (2019) 736e746738Epigenetics has been associated with cancer since the 1980s, but
only more recently has the potential for clinical use in form of
improved tumour classification, as epigenetic biomarkers or as
novel targets of therapy [11,12]. In this review wewill explore some
of the key areas where cancer epigenetics play a current role in
solid visceral tumours in general and for selected solid organ can-
cers specifically. As frequently investigated cancer models and
public health burden, we chose to focus on colorectal and breast
cancer. Also, we chose hard to treat cancers with a current overall
poor prognosis, such as pancreatic cancer and hepatocellular car-
cinoma. All the cancer types discussed herein are frequently rep-
resented in the scope of surgical oncology practice and should thus
be of relevance to the practicing clinician. Current updated reviews
from the past 3e5 years period are selected to allow the interested
reader to seek further in-depth knowledge to specific topics.
Methods
This narrative review was based on a literature search of the
PubMed database covering the last decade, with a strong emphasis
on papers and studies published over the last five-year period (up
to January 10th, 2019). Authorative reviews were chosen to allow
the interested reader to search further indepth knowledge and
studies relted to the selected cancers were chosen as examples. We
acknowledge that the search is not exhaustive and apologize to
those authors whose work could not be cited.
The mechanisms of epigenetic regulation
Cancer has long been viewed simply as a genetic disease.
Changes to the human genetic code e such as mutations, copy
number alteration, insertions, deletions, or recombinations e are
particularly well suited to induce persistent phenotypic changes in
cancer. However, sporadic genetic events occur at a low frequency
and are thus not a very efficient way of causing malignant trans-
formation [13]. Some cancer cells overcome this bottleneck by
acquiring DNA repair defects, thus boosting the mutation rate -
such as seen in mismatch repair deficient tumours that lead to highFig. 3. Epigenetic regulation through readers, writers and erasers.
Regulators that write the marks are known as ‘writers’ and include DNA methyltransferase
marks and include regulators such as the bromodomain, chromodomain, and tudor protein
such as histone deacetylases (HDAC) and histone demethylases (HDM); and remodellers of t
nucleosome remodelling complex. As epigenetic alterations are reversible, inhibitors targetoccurrence of microsatellite instability (MSI) throughout the
genome [14,15]. Mechanisms of epigenetic control offer an alter-
native path to acquiring stable oncogenic traits [9,16].
Epigenetic states are flexible, persist through multiple cell di-
visions and, influence the cellular phenotype. Broadly, epigenetics
occurs through 3 different forms as has recently been described in
detail elsewhere [2,3]; through methylation of DNA; post-
translational modification of nucleosomal histones and, lastly,
through organization of higher-order chromatin structure (Fig. 2).
Closely related mechanisms are increasingly being tied to epige-
netic regulation and control of the ‘epigenetic landscape’, such as
non-coding RNA [17,18] (as either small or long non-coding RNAs)
and will be discussed further below. Previously labelled “junk
DNA”, the non-coding RNAs are increasingly recognized as key
regulators in several aspects to health and disease, including
cancer.
Each of the epigenetic levels can be influenced through inheri-
ted genetic information, through external exposures and ongoing
biological processes, such as aging. Epigenetic changes may lead to
cancer development. Notably, altered genetic information in the
cancer itself may also promote epigenetic changes (Fig. 1) and
further development of tumour heterogeneity. This may also be
influenced further by the effects of chemotherapy [2], leading to
epigenetic changes or selection of subclones that bears particular
epigenetic marks. This adds complexity to the understanding and
research into epigenetics in cancer yet provides opportunities for
finding novel therapeutic targets.
Several classes of epigenetic regulators (Fig. 3) exist and they are
broadly defined as ‘writers’, ‘readers’ and ‘erasers’ [3,19,20]. As
epigenetic alterations are reversible, inhibitors targeting the
epigenetic processes may be promising anticancer strategies.
Briefly, regulators that write the marks are known as ‘writers’ and
include DNA methyltransferases, histone methyltransferases, and
histone acetyltransferases. ‘Readers’ are, as derived from the name,
reading the marks and include regulators such as the bromodo-
main, chromodomain, and tudor proteins. Lastly, regulators that
can erase marks are called ‘erasers’, and among these are examples
such as histone deacetylases (HDAC) and histone demethylasess, histone methyltransferases, and histone acetyltransferases. ‘Readers’ are reading the
s. Regulators that can erase marks are called ‘erasers’, and among these are examples
he chromatin, such as components of the SWI/SNF (SWItch/Sucrose Non-Fermentable)
ing the epigenetic processes may be promising anticancer strategies.
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the SWI/SNF (SWItch/Sucrose Non-Fermentable) nucleosome
remodelling complex [20,21]. Mutation of specific epigenetic
modifiers occurs frequently in a variety of cancers demonstrates
that altered epigenetic regulation may play an important role in
cancer development (Fig. 1), yet may also be a bystander effect of
carcinogenesis itself [22].
The best-known and most explored epigenetic alteration is DNA
methylation [23,24] (Fig. 4). DNA methylation has critical roles in
the control of gene activity and the architecture of the nucleus of
the cell. Histones serve as molecular structures that participate in
the regulation of gene expression. Consequently, chemical modifi-
cation of histonesmay alter gene expression. Histones contribute to
epigenetic post-translational modifications through lysine acety-
lation, arginine and lysine methylation, and serine phosphorylation
- modifications that affect gene transcription and DNA repair [25].
In humans, DNA methylation occurs in CpGs (Fig. 4). Regions in the
DNA that contain many adjacent cytosine and guanine nucleotides
are called ‘CpG-islands’ (… CGCGCGCGCG …. ). CpG islands are not
randomly distributed in the genome but rather often found in the
regulatory region of many genes (approximately 40% of the pro-
moters of human genes). These islands are usually not methylated
in normal cells. While CpG islands are usually unmethylated in
normal cells, and the genes downstream of these unmethylated
promoters are transcribed in the presence of transcriptional acti-
vators, genomic platforms have confirmed that almost 10% of nor-
mally unmethylated promoter CpG islands, many of them
belonging to tumour suppressor genes, become abnormally
methylated and thus silenced in cancer [26,27] promoting carci-
nogenesis. In colorectal cancer [15,28], a CpG-island methylator
phenotype (CIMP) has been recognized as a separate molecular
group (besides microsatellite instable and chromosomal instable
tumours) that has distinct clinical and pathological characteristics
[29]. For one, prognosis is demonstrated to be significantlyFig. 4. Overview of DNA methylation and effects.
DNA methylation occurs in the context of chemical modifications of histone proteins by the
precedes a guanine; these are called dinucleotide CpGs. Regions in the DNA that contain m
refers to the phosphodiester bond between the cytosine and the guanine.worse for the CIMP positive group in both colorectal [30] and he-
patocellular carcinoma [31].
Heterochromatin is a closed chromatin conformation that is
often associated with DNA methylation and inactive gene tran-
scription. In contrast, the euchromatin state is in an open confor-
mation and associates with active gene transcription, presumably
secondary to increased transcription factor binding. DNA methyl-
transferases and Methyl-CpG-Binding Domain proteins (MBDs)
work with histone-modifying enzymes for regulating all DNA-
templated processes including transcription, repair, replication,
and recombination [23,26,32]. Histone N-terminal tails can
undergo many chemical modifications, including acetylation,
methylation, phosphorylation, and ubiquitination (Fig. 5).
Depending on the combination of modifications in a specific
genomic region, chromatin remainsmore or less packed, blocking or
permitting the nuclear processes. Importantly, this histone code is
not static but rather is changing in a context-dependent manner. As
such, it can both facilitate or repress gene transcription. Histone
modifications are still being discovered and are found in novel
combinations, highlighting the flux of knowledge in this field. The
influence of these marks on other histone modifications is referred
to as “histone crosstalk” and is of crucial importance for the tran-
scriptional readout of a gene [21,26]. The various enzymes respon-
sible for suchmodifications throughout histone tails include histone
acetyltransferases (HATs), multiple classes of histone deacetylases
(HDAC classes I, II, III and IV) and sirtuins (a HDAC class III, which are
NAD þ dependent), histone methyltransferases (HMTs), histone
demethylases (HDMs), histone kinases and phosphatases, histone
ubiquitin ligases, and deubiquitinases (as reviewed in detail in
Ref. [26]). Consistently, with the fact that disruption of normal
patterns of covalent histone modifications is a defined cancer hall-
mark many such enzymes that add or remove (writers and erasers)
these chemical groups, and also those that recognize them (readers)
are mutated or misregulated in cancer (see Fig. 3).addition of a methyl group to DNA at the 5-carbon of the cytosine pyrimidine ring that
any adjacent cytosine and guanine nucleotides are called ‘CpG-islands’. The “p” in CpG
Fig. 5. Overview of histone modifications. Histone modifications regulate access to DNA and have a major role in the reading, transcription and alteration of DNA. Different tail
modifications result in differential effects on the accessibility and stability of DNA packed around histones.
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account for only 2% of the entire DNA, yet are the most thor-
oughly investigated parts of the genome. The remaining part of
the genome (that is, the part not coding for proteins) is made up
of noncoding RNAs (ncRNAs) [17,18]. Previously dubbed ‘junk
DNA’ due to the believed lack of function, the non-coding part of
DNA is now demonstrated to be involved in anything from
embryogenesis to cancer development. As such, ncRNAs include
microRNAs (miRNAs), PIWI-interacting RNAs (piRNAs), small
nucleolar RNAs (snoRNAs), small interfering RNAs (siRNAs), and
long noncoding RNAs (lncRNAs). While miRNAs are probably the
most investigated and best understood of these in cancer [33,34],
there is an increasing interest in understanding the other
ncRNAs as therapeutic strategies may be developed to counteract
these perturbations [17]. The ncRNAs are epigenetically regu-
lated in carcinogenesis and metastases development and
consequently sculpting the epigenetic profile of a cancer cell.
Consequently, ncRNA are modulating the expression of other
RNA molecules too [17,33] and by that not only affect the DNA
methylation status of certain genomic loci but also interact with
histone-modifying complexes, changing the structure of the
chromatin itself [17].
Epigenetics alterations from cradle to grave
Epigenetic marks change during foetal development (thus,
turning mechanisms on/off), through adult life (through various
exposures), and occur throughout the aging process [4,35e38],
Fig. 1. Epigenetics are influenced by a number of external and in-
ternal exposures, such as physical activity and nutrition [6,39,40].
Some changes play an important role in the establishment and
regulation of gene programs, but others seem to occur without any
apparent known physiological role. Nutritional patterns, physical
activity and medications can affect the epigenome [35,41]. The
potential use of natural epigenetic modifiers in the chemopreven-
tion of cancer is increasingly explored and may provide opportu-
nities for lifestyle intervention and for prevention of cancer [42].
Theway inwhich energy is used in cells is determined under the
influence of environmental factors such as nutritional availability[43]. Metabolic adaptation is mainly achieved through the modu-
lation of gene expression [44,45], and may also involve epigenetic
mechanisms that enable long-term regulation. Nutrients and their
metabolites may influence on the epigenome through acting as
substrates or as coenzymes for epigenetic-modifying enzymes,
while other epigenetic regulators may influence metabolic genes in
a way that lead to a shift in energy flow. These findings suggest the
concept of metabolism-epigenome crosstalk that may contribute to
the formation of a long-term metabolic phenotype [43]. Epigenetic
regulation of metabolism [46] is relevant to understanding the
development of obesity and pathogenesis of related metabolic
disorders. Epigenetic alterations that occur through nutritional
conditions and microbial exposures before or after birth may affect
disease risk in adulthood [47] e decades after the metabolic events
took place (Fig. 1).
Age-dependent loss of global methylation, together with
hypermethylation of CpG islands associated with cancer-related
genes, may be influenced by nutritional and metabolic factors
[48]. Several compounds of nutrition, such as folates and vitamins,
are essential for the maintenance of normal DNA methylation.
Folate metabolism is known to modify epigenetic mechanisms
under experimental conditions, and more recent findings has
explored the important roles of vitamin C and D in maintenance of
the epigenome [49,50]. Further, most cancer cells exploit metabolic
pathways for their hyperproliferative activity [51], while metabolic
reprogramming leads to aberrant epigenetic regulation in some
cancers [52]. Thus, epigenetics influences human cells in a number
of ways, from conception and in the prenatal phase, through birth
and long into aging. From a public health perspective, a better
understanding may open avenues into preventive strategies and
early detection or risk through epigenetic mechanisms, markers
and profiles.
Epigenetics in cancer evolution
Genome-wide sequencing has shown that all cancers have
1000s of somatic genetic and epigenetic alterations that are not
present in the patient's germline genome. Notably, only a very
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with a growth advantage of the cancer cell over other normal cells
in the surroundings [13]. The remaining alterations are ‘passengers’
found in tumour cells only because they occurred coincidentally
during the long march toward carcinogenesis. Of the more than
20,000 genes in the human genome, only some 200 have been
shown to act as driver genes for common cancers [13,53]. What is
more, these genes appear to function through a limited number of
cancer pathways.
Notably, tumours evolve in three broad phases e the break-
through, expansion and invasive phases [53] (Fig. 1). In the break-
through phase, a cell acquires a driver-gene mutation and begins to
proliferate abnormally [53]. Known cancer mutation rates suggest
that these further mutations are unlikely to occur without a large
increase in cell number during the breakthrough phase [13]. The
mutation initiating the breakthrough phase is often very specificd
a limited number of growth-regulating pathways seem able to
initiate neoplasia in a given cell type [54]. As tumours progress, this
specificity seems to be progressively lost, so a greater number of
driver genes can transform a cell from the expansion phase to the
invasive phase. Knowing that so few genetic mutations are required
in neoplastic transformation could possibly be explained by the
added influence of epigenetic alterations [13].
The interaction between the genome and epigenome
throughout the process of carcinogenesis is not fully understood
[9]. Epigenetic reprograming of neoplastic cells have been proposed
[55,56], with the idea that the epigenome and genome interact
synergistically to evolve to stressors to ensure survival (Fig. 1).
Epigenetic regulation provides a degree of plasticity, thus granting
cancer cells the ability to repress the expression of specific genes in
response to stresses and stimuli. An example of this is in cancer
metabolism, where dynamic changes in oxygen tension or nutri-
ents leads to epigenetic reprogramming, thus enabling cell survival
and evolution. Furthermore, cancer cells may acquire mutations in
genes coding specific transcription factor drivers which modulate
collaborating chromatin regulators, thus dynamically regulate their
epigenetic circuits to rewire differentiated cancer cells into stem-
like cells, leading to upregulation of cancer growth [55]. This
acquisition of stem-like characteristics is linked with the develop-
ment of metastasis and spread of disease, as cells have greater
plasticity to move, migrate and survive. Indeed, the metastatic
process is a complex and dynamic process consisting of numerous
steps and interactions [56e59] e even among the cancers cells that
reach the circulation it is estimated that less than 1 in 10000 may
have a metastatic potential. Thus, genetic mutations may not be a
causal factor for the transition from primary tumour to metastatic
lesion. Rather, as epigenetic changes are dynamic they may play an
important role in determining metastatic phenotypes [56,57]. In an
analogy to the driver and passenger mutations mentioned above,
concepts have now emerged for “driver epigenetic” events that
may influence the metastatic potential. Such ‘epi-driver’ and ‘epi-
passenger’ events in metastasis may provide for better under-
standing of the biological processes and also provide for new areas
for therapeutic targets [56,57,60]. Taken together, the epigenome
cooperates with the genome as cancers develop and eventually
metastasize [56,57] with the potential for exploring novel bio-
markers of risk or monitoring of disease and, drugable targets for
therapy.
Potential clinical implications of epigenetics
Several classes of epigenetic regulators of writers, readers, and
erasers have been implicated in mechanisms leading to intra-
tumoural heterogeneity and chemotherapy resistance [61e63]. The
clinical implications are multifold and is likely to affect how weapproach cancer therapies in the future. For example, the ability to
biopsy tumour changes in subclones at time of diagnosis and dur-
ing follow up may help tailor therapy to the epigenetic and genetic
makeup of the tumour [54]. Further, epigenetic marks may be used
as predictive or prognostic biomarker of treatment success, e.g. for
measure of response or as indicator of recurrence. Finally, specific
epigenetic drugs may be used together with conventional drugs to
achieve a more tailored and specific response to the specific cancer
under treatment [20,57,60,64,65].
Epigenetic therapies, in which the goal is to reverse these
changes, are now in routine clinical use for haematological malig-
nancies [12,66]. The application of epigenetic therapies in the
treatment of solid tumours is also emerging as a potential thera-
peutic option with multiple phase I and II studies underway
(Table 1) [20,67]. The limitations posed by cancer treatments
involve (among others) the unintended epigenetic modifications
that may result in exacerbation of tumour progression e a side
effect that clearlywould contradict the use of epigenetic therapy for
curative purposes. The specificity restrictions (i.e. tumour specific
effect not involving the normal epigenome) posed by epigenetic
therapies and ways to address such limitations is presented in
detail elsewhere [68]. Further, with the next generation of targets
and drugs, there is hope that novel epigenetic therapies may
improve drug targeting and drug delivery, optimize dosing sched-
ules, and improve the efficacy of pre-existing treatment modalities,
such as chemotherapy, radiation, and immunotherapy [69].
Classification and use of epigenetic biomarkers
Tumours have in the past been classified based on their (likely)
tissue of origin and differentiation and grade. This still represents
the mainstay for diagnosis and prognosis, but increasingly epige-
netic features help classify tumours into distinct therapeutic and
prognostic classes.
The ability to identify high- and low-risk patients based on
circulating or tissue biomarkers in cancer is still poor. Molecular
biology has, over the years, given insight into basic principles of
cancer initiation and development and increasingly these are being
exploited as biomarkers, and several epigenetic markers or tools
have been proposed in various tumours. This include aberrations
increasing risk of tumour development, (epi-) genetic changes
associated with the stepwise progression of the disease, and errors
predicting response to a specific treatment. Because several
epigenetic changes occur before histopathological changes are
present, they can serve as biomarkers for cancer diagnosis and risk
assessment [70]. Many cancers may remain asymptomatic until
relatively late stages; in managing the disease, efforts should be
focused on early detection, accurate prediction of disease pro-
gression, and frequent monitoring [25]. Based on epigenomic in-
formation, biomarkers have been identified that may serve as
diagnostic tools; some such biomarkers may also be useful in
identifying individuals who will respond to therapy and, poten-
tially, live longer [15,25,27,59,70e72]. Recently, in a multicentre
study the investigators were able to predict a primary cancer of
origin in 87% of 216 patients who had a cancer with unknown
primary by using DNA methylation profiling [73]. Determining the
epigenetic landscape of tumours is key to the success of this and
has been performed in several tumour types, some of which are
presented as examples in paragraphs below.
One area in which epigenetics has demonstrated considerable
promise is in the development of liquid cancer biopsies [74]. Ex-
amination of methylation patterns on cell-free DNA or circulating
tumour DNA has been proposed in multiple malignancies as
minimally invasive diagnostic cancer test. These tests work in a
variety of ways and are typically based on PCR amplification assays,
Table 1
Summary of ongoing trials of epigenetic therapies.
Authors Year Compound Phase Status Target Disease Recruiting?
Azad et al. 2013 Azacitidine with nab-
Paclitaxel and
Gemcitabine
II Recruiting to March
2018 (last update)







Hellmann et al. 2017 Guadecitabine and
Mocetinostat with
Pembrolizumab
I Recruiting to June 2018
(last update)




Stage IIIb or IV non-
small cell lung cancer
Active recruitment
ongoing
















Velcheti et al. 2016 Decitabine,
Tetrahydrouridine,
Nivolumab
II Recruiting to December
2017 (last update)
Decitabine - hibition of DNA
methyltransferase
Tetrahydrouridine - Inhibitor of
cytidine deaminase
Non-small cell lung




Munster et al. 2015 Vorinostat,
Pembrolizumab,
Tamoxifen






women or men with
stage IV breast cancer
Active recruitment
ongoing
Shah et al. 2011 Azacitidine, Oxaliplatin,
Epirubicin,
Capecitabine
I Recruited and results
expected November
2018









Brahmer et al. 2013 Azacitidine, Entinostat,
Nivolumab
II Recruiting to October
2017 (last update)









Fandi et al. 2015 Azacitidine or placebo,
Pembrolizumab
II Recruited and first
results posted May
2018
Azacitidine- Inhibition of DNA
methyltransferase




Yip et al. 2018 Phenelzine Sulfate and
Nanoparticle albumin-
bound Paclitaxel
I Recruiting to April 2018
(last update)








Preskitt et al. 2016 Curcumin and 5-
Fluorouracil
I Unknown Curcumin - Histone deacetylase
inhibitor
Metastatic colon cancer Unknown
Plimack et al. 2017 Guadecitabine and
Atezolizumab
II Recruiting to June 2018
(last update)







Shu et al. 2017 Guadecitabine (SGI-
110) and Durvalumab
or Tremelimumab
I Recruiting to June 2018
(last update)
Guadecitabine - Inhibition of
DNA methyltransferase
Small cell lung cancer Active recruitment
ongoing
Doroshow et al. 2015 Deoxycytidine (TyCyd) I Recruiting to July 2018
(last update)












I/II Not recruiting (last
update June 2018)














Examples of active trials updated in past 4 years (until December 2018) on ClinicalTrials.gov testing epigenetic therapies in solid tumours.
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itself. Simply, they work to identify cancer-specific methylation
patterns at specific loci. A range of bodily fluids may be used in this
way, with blood and urine liquid biopsy tests currently in advanced
development [72]. The performance of these methylation-based
assays has a significant advantage over genomic cell free DNA
testing. In early stage or low-grade disease, methylation patterns
are more prominent than the low number of genomic mutations
that occur early in tumour development [73]. So far, methylation
based liquid biopsy has been investigated in multiple malignancies,
including breast, colorectal, pancreas and lung [74e76]. Results and
quality of these studies have been variable, but the specificities and
sensitivities are promising in the populations they were tested in etypically around 90%. One of the more challenging questions for
liquid biopsies is where these will be of most use clinically, but
there are several useful roles to both diagnostic, prognostic and
predictive biomarker use [74,75]. There are likely to be roles for
epigenetic biomarkers in early detection and follow-up, however, a
universal test for all cancers which would have the most utility in a
public health setting remains someway off. However, a recent
multipanel test in >1000 patients showed considerable potential
for early diagnosis and detection of cancer at a time when the
disease would be potentially curable (by surgery) as tested across a
spectrum of cancer types [76]. Furthermore, liquid biopsy using
methylation assays provides limited information about tumour
biology and whether these tests could enable precision medicine in
T.M. Drake, K. Søreide / European Journal of Surgical Oncology 45 (2019) 736e746 743a neo-adjuvant setting without formal biopsy is unknown.
Colorectal cancer
For the assessment of primary colorectal tumours there are at
least 3 suggested classifications that comes into consideration [15].
One is a hyper mutated group that includes defective DNA
mismatch repair with microsatellite instability and POLE (DNA
polymerase epsilon) mutations (about ~15% of CRC patients), con-
taining multiple frameshifted genes and BRAFV600E. The second is a
non-hyper mutated group with multiple somatic copy number al-
terations and aneuploidy, previously known as chromosomal
instability (CIN) type of tumours (in ~85%), containing oncogenic
activation of KRAS and PIK3CA and mutation and loss of hetero-
zygosity of tumour suppressor genes, such as APC and TP53. A third
group is named CpG islandmethylator phenotype (CIMP) type CRCs
(in ~20%) that overlap greatly with microsatellite instability CRCs
and some non-hyper mutated CRCs [77]. CIMP tumours have
methylated CpG islands and epigenetic alterations are essential in
these cancers. Lastly a fourth group (or, a modifier group) is named
after Elevated Microsatellite Alterations at Selected tetranucleotide
(EMAST) repeats (found in up to ~60% of CRC, but also in a range of
other cancer types [14]) that associates with metastatic behaviour
in both hyper mutated and non-hyper mutated groups.
Components from these classifications are now used as diag-
nostic, prognostic, and treatment biomarkers [15,78], yet universal
agreement on such a new classification has not been reached with
alternative proposals published [79,80] and several negative
studies exist [81]. However, several studies have also reported lack
of a clinical role of epigenetic markers so further work needs to be
done to refine the role of epigenetics in the clinical management of
CRC.
Pancreatic cancer
Pancreatic ductal adenocarcinoma (PDAC) has an extremely
poor prognosis, with limited effective treatments. Alterations in
epigenetic regulation are frequently found in PDAC [82], particu-
larly in the regulation of genes involved with oncogenic signalling,
with metabolic alterations and, in the metastatic process
[45,83e85]. The epigenetic landscape of PDAC may be broadly
classified into 3 groups; basal-like tumours with enhancers across
several important oncogenic signalling pathways, ‘classical’ tu-
mours with enhancers (pancreatic development genes) and ‘clas-
sical’ tumours with active promoters across similar regions as the
second group. The activity of epigenetic regulators in pancreatic
cancer, particularly the first subgroup, is associated with upregu-
lation of genes responsible for aggressive tumour biology (EGFR,
ErbB), deregulation of cell differentiation (YAP1, MYC, E2F7, HEY1)
and promotion of metastasis through epithelial mesenchymal
transition (HIPPO, WNT family, TGFb). Epigenetic regulation across
all these groups was found to silence tumour suppressor genes.
Several compounds have been trialled, targeted to epigenetic al-
terations in tumours, including trials of curcumin (a p300 histone
acetyltransferase inhibitor) and Histone deacetylase inhibitors
(HDACi) such as Vorinostat [86]. Some patients have demonstrated
response to these therapies but much more research is required to
draw meaningful conclusions. It is currently hoped that immuno-
therapy and epigenetic targets, with or without conventional
chemotherapy, may enhance response rates and effect in patients
with PDAC. A detailed overview of ongoing research, trial sand
mechanisms is provided elsewhere [86].
Epigenetic alterations in pancreatic cancer, in particular cell-free
DNA and measurement of DNA methylation in pancreatic juice,
offers a minimally invasive approach to diagnostics and prognos-
tication. Panels of epigenetic biomarkers have been demonstrated
to achieve sensitivities and specificities of 80 to upwards of 90%,however, these studies lack meaningful validation thus precluding
their use in routine practice [87,88]. However, recent panels have
showed promise for liquid biopsy technology as a pre-diagnostic
screening tool for patient with PDAC.
Hepatocellular carcinoma
Hepatocellular carcinoma (HCC) has a complex aetiology, typi-
cally evolving off the background of inflammatory liver diseases.
Multiple integrative analyses of HCC have uncovered a complex
landscape of three, distinct molecular subtypes of HCC. The first
appears to be associated with normal body weight, Asian ethnicity
and hepatitis B virus infection, whereas the second and third sub-
types harbour mutations across CTNNB1, TERT promoters and, for
the third subtype, in the TP53 gene. In HCC, there are several levels
of epigenetic dysregulation involved in carcinogenesis and the
stepwise progression towards metastatic or incurable disease
[31,58,89,90]. For one, the CDKN2A tumour suppressor gene is
found to be frequently silenced by DNA hypermethylation [91].
Further epigenetic alterations are found in the third subtype of HCC
which lead to chromosomal and genome instability, in particular,
the hypomethylation of multiple CpG sites [89]. Micro-RNA-122
(miR-122) expression is found to be aberrant in IDH1/2 mutant
HCC, with reduced expression throughout tumour tissues which is
associated with poor survival. It is thought miR-122 has tumour
suppressor functions by modulating the effects of TP53 through
Mdm2 [92,93]. Study of the methylation status and copy number
variation found in HCC identified aberrant DNA methylation and
copy number alteration was significantly associated with poorer
survival, although this observation was not further developed as a
tool for prognostication. Circulating tumour DNA methylation has
found to be an accurate test, with very high sensitivity and speci-
ficity for detecting HCC and aiding in treatment stratification [94].
Little in the way of clinical trials of agents targeting epigenetic al-
terations have been performed for HCC, however, the concomitant
use of HDAC inhibitors alongside Sorafenib has been explored with
some promising results in small trials [95,96].
Breast cancer
Compared to other tumour types, the epigenetics of breast
cancer are relatively well characterized and are known to play an
important role in disease behaviour. Epigenetic drivers are found
early in breast cancer carcinogenesis, including early DNA
methylation and alteration in chromatin states [16]. Furthermore,
lncRNAs and miRNAs have been found to affect wide numbers of
genes, regulating their function and driving carcinogenesis and the
development of intratumoural heterogeneity. Throughout the
evolution of breast cancer, epigenetic reprogramming of these tu-
mours occurs and have been found on the APC, CDH1 and CTNNB1
genes. Distinct patterns of reprogramming have been found
through from ductal hyperplasia, ductal carcinoma in-situ to
invasive carcinoma. Interestingly, the finding of distinct methyl-
ation patterns is not just confined to malignant breast cancer cells
[97]. Adjacent, histopathologically normal, tissue has been found to
demonstrate similar DNA methylation profiles to cancerous cells
revealing a field effect. Epigenetic profiling of tumours and circu-
lating DNA has raised the possibility that measurement of DNA
methylation may be used to predict survival clinically. So far,
however, few of these have made it to clinical practice and or trials
of epigenetic alterations to guide cancer therapy [98,99]. As with
other tumour types, HDAC inhibitors have been trialled in breast
cancer, with varying degrees of success and at present there is a
lack of convincing placebo-controlled data from a large trial to
support routine clinical use [100,101].
Therapies targeting DNA methylation have also been trialled in
breast cancer, DNA methyltransferases inhibitors (known as
T.M. Drake, K. Søreide / European Journal of Surgical Oncology 45 (2019) 736e746744DNMTs) remove methyl groups from DNA [102,103]. They are used
in haematological malignancies, however, their use in solid tu-
mours has not progressed past clinical trials due to their poor side-
effect profiles [104]. The compounds, Azacitidine, Decitabine and
Zebularine typically act by forming covalent bonds with DNA
methyltransferases and thus cause them to become ‘trapped’ and
unable to methylate DNA further. To date, trials have been disap-
pointing, with very limited clinical effects demonstrated from these
therapies.
Potential research caveats in epigenetics
Generalisability and reproducibility in using epigenetic markers
for classification and diagnosis has been hampered by the lack of
standardized and unified protocols and analytical designs. For
example, we found in a previous study that the call of CIMP clas-
sification would deviate substantially between cases depending on
what definitions, genes and panels where used for defining CIMP
status [105]. A total of 16 different definitions of CIMP were iden-
tified in a systematic review [106]. In that paper, all studies on CRC
prognosis according to the various definitions of CIMP were
searched for and some 36 studies were identified [106]. Of the 36
studies, 30 (83%) reported the association of CIMP and CRC prog-
nosis and 11 (31%) reported the association of CIMP with survival
after chemotherapy. Most studies reported a poorer prognosis for
patients with CIMP-positive CRC than with CIMP-negative CRC.
Inconsistent results or varying effect strengths could not be
explained by different CIMP definitions used. Response to specific
therapies according to CIMP status was inconsistent across studies.
As the authors conclude, comparative analyses of different CIMP
panels in the same large study populations are needed to further
clarify the role of CIMP definitions and to find out howmethylation
information can best be used to predict CRC prognosis and response
to specific CRC therapies. From both studies [105,106] goes the
notion that better standardization and agreement between studies
are needed.
Future research
Although the human genome has beenwell characterized, along
with somatic mutational drivers of cancer, relatively little is known
about how various epigenetic alterations interact with one another
and the genome. The landscape of DNA methylation, micro-RNAs
and to some extent long non-coding RNAs have been studied
with next-generation approaches in initiatives such as The Cancer
Genome Atlas, however other epigenetic elements remain poorly
characterized.
Modelling how epigenetics interacts with the cancer genome
and subsequently the transcriptome will be key to effective treat-
ment stratification and identifying how epigenetic alterations can
be therapeutically targeted. This may be achieved in multiple ways,
however, use of computational in-silico methods, including ma-
chine learning, may lend themselves well to identifying potential
interactions which may then be explored in high-throughput in-
vitro and in-vivo studies. These computational approaches are
highly complex as they are required not only to analyse genome
wide data, but also to model the complex interactions across
pathways and at multiple levels of the epigenome. Technologies
such as CRISPR-Cas9 and Cre-lox recombination could be used to
accomplish this. These technologies permit efficient editing of
some nucleic acid components of the epigenome and may be
turned on or off using elements dependent on external stimuli
provided by researchers.
Detection of aberrant DNA methylation is being developed as
biomarkers for prognostic and diagnostic purposes ingastrointestinal cancers [107]. Novel ways of obtaining samples,
such as liquid biopsies, may lead to less invasive and more clinical
useful tests in the future [74]. Prognostication studies based on
epigenetic elements are published [81], but few have made it into
routine clinical practice. An example of a commonly used epige-
netic test is measurement of the methylation status of the MGMT
(O-6-methylguanine-DNAmethyltransferase) gene in glioblastoma.
Methylation of this gene, a key protein responsible for maintaining
genome stability through mismatch repair, guides use of Temozo-
lomide therapy, with patients having methylation of the MGMT
promoter having better responses to therapy. The careful validation
and study of this through molecular studies and into randomized
control trials has enabled this epigenetic marker to reach the clinic
and improve cancer outcomes for patients. However, many epige-
netic prognostication studies lack this approach, commonly have
low sensitivity and specificity for isolated markers, and do not
consider a ‘multi-omic’ approach. To have clinical utility, re-
searchers must be careful not to consider the epigenome in isola-
tion, as its primary role appears to be regulation of the genome and
transcriptome. Recent developments in technology, such as single-
cell omics technology [108] tries to overcome these hurdles and
may have a greater clinical impact in the near future. Lastly,
recognition of variation in exposure and how epigenetic regulation
across global populations may drive risk, influence cancer pheno-
type and potentially present with different outcomes and re-
sponses to therapies is necessary [109]. This requires investigation
across diverse populations and from various regions of the world
for valid and robust results.
Conclusion
The epigenetic regulation of cancer is complex and not yet fully
understood. Several mechanisms of epigenetic regulation exist and
already are known to have implications for cancer therapies and
disease prognostication. Surgical oncologists must be aware of
recent developments in the area to understand the application of
epigenetics to clinical practice and to improve research to benefit
patients.
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